Adrenocortical Carcinoma Market Forecast upto 2034—Insights into Emerging Therapies and Market Trends
The adrenocortical carcinoma market in the 7MM is anticipated to boost during the forecast period (2025–2034), due to the launch of emerging therapies such as CY‑101 from Cytovation and OR‑449 from Orphagen Pharmaceuticals, and others, and the increasing cases of ACC.
DelveInsight's Adrenocortical Carcinoma Market Insights report includes a comprehensive understanding of current treatment practices, emerging adrenocortical carcinoma drugs, market share of individual therapies, and current and forecasted adrenocortical carcinoma market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Key Takeaways from the Adrenocortical Carcinoma Market Report According to DelveInsight's analysis, the total adrenocortical carcinoma market size is expected to grow from USD 30 million in the 7MM in 2024.
in the 7MM in 2024. The United States accounts for the largest market size of adrenocortical carcinoma, in comparison to EU4 (Germany, Italy, France, and Spain) and the UK, and Japan.
Based on DelveInsight's assessment in 2024, the 7MM had 1,250 incident cases of ACC, and it is projected that these cases will experience an increasing growth trend with a significant CAGR during the forecast period (2025−2034).
incident cases of ACC, and it is projected that these cases will experience an increasing growth trend with a significant CAGR during the forecast period (2025−2034). Prominent companies, including GlaxoSmithKline, Bristol Myers Squibb, Merck, Cytovation, Enterome, Orphagen Pharmaceuticals, and others, are actively working on innovative adrenocortical carcinoma drugs.
and others, are actively working on innovative adrenocortical carcinoma drugs. Some of the key adrenocortical carcinoma therapies in the pipeline include CY-101, OR-449, dostarlimab, nivolumab + ipilimumab, and pembrolizumab, EO2401 + Nivolumab, and others. These novel adrenocortical carcinoma therapies are anticipated to enter the adrenocortical carcinoma market in the forecast period and are expected to change the market.
Discover which adrenocortical carcinoma medications are expected to grab the market share @ Adrenocortical Carcinoma Market Report
Adrenocortical Carcinoma Market Dynamics
The adrenocortical carcinoma market dynamics are anticipated to change in the coming years. The availability of surgical options such as adrenalectomy provides a practical approach for removing the diseased adrenal gland, thereby improving access to treatment. Mitotane remains the mainstay treatment for ACC, with its exclusive status as an 'Off-Patent, Off-Exclusivity Drug without an Approved Generic' in the Orange Book reinforcing its dominant position.
There is significant potential for collaboration among medical professionals, researchers, and patient advocacy organizations to raise disease awareness and broaden access to care. The limited therapeutic landscape for ACC presents a strategic opportunity for new players to enter and expand within the market.
Furthermore, many potential therapies are being investigated for the treatment of adrenocortical carcinoma, and it is safe to predict that the treatment space will significantly impact the adrenocortical carcinoma market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the adrenocortical carcinoma market in the 7MM.
However, several factors may impede the growth of the adrenocortical carcinoma market. The reliance on surgery as the main treatment for ACC, due to the limited availability of systemic therapies, highlights a weakness stemming from a lack of diverse treatment options. ACC's rarity and the small number of affected patients make it difficult to conduct large-scale clinical trials, complicating the development of evidence-based treatment protocols and assessment of new therapies.
Resistance to current treatments like mitotane monotherapy, or their limited effectiveness, often leads to poor patient outcomes and represents a major challenge. Additionally, the ultra-rare nature of ACC limits access to funding and resources for research and development, posing a significant barrier to progress.
Moreover, adrenocortical carcinoma treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the adrenocortical carcinoma market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the adrenocortical carcinoma market growth.
Adrenocortical Carcinoma Treatment Market
Surgical removal is the primary treatment option for localized adrenocortical carcinoma. However, many patients are diagnosed at advanced stages, where surgery alone is unlikely to be curative. Chemotherapy, particularly mitotane, is the only FDA-approved drug for ACC, though its effectiveness varies, and it often causes substantial side effects.
Complete surgical excision remains the only potentially curative option. For localized cases, adjuvant therapies are used to reduce the risk of recurrence. In cases where the tumor is unresectable or has metastasized, treatment shifts to palliative care.
First-line treatment strategies for ACC are personalized, taking into account the patient's prognostic profile. For those with good performance status and aggressive disease, a combination regimen like EDP-M (etoposide, doxorubicin, cisplatin, and mitotane) is often employed. Patients with less aggressive disease may be treated with mitotane alone, sometimes alongside locoregional interventions.
Despite some efficacy, EDP-M is not curative, and the overall prognosis remains poor. Second-line options such as streptozocin with mitotane (S+M) and gemcitabine with capecitabine (G+C) show limited effectiveness, with response rates around 10%. G+C is generally well tolerated but lacks strong molecular predictors of response.
Temozolomide, used as a third-line option, shows anti-cancer activity in laboratory settings. While some patients experience disease stabilization, its clinical benefit is modest, and research is ongoing to determine which patient subgroups may respond best.
Looking ahead, future treatment advances may include new chemotherapies, angiogenesis inhibitors, and targeted small-molecule drugs. These innovations, driven by deeper molecular insights into ACC biology, offer potential for improved therapeutic outcomes.
Learn more about the adrenocortical carcinoma treatment options @ Adrenocortical Carcinoma Drugs Market
Adrenocortical Carcinoma Emerging Drugs and Companies
Research and development efforts in adrenocortical carcinoma remain limited due to its classification as an ultra-rare disease, resulting in a sparse pipeline with only a few therapies currently in Phase II, Phase I/II, or preclinical stages. Among the investigational treatments being evaluated in clinical trials are Dostarlimab (GlaxoSmithKline), the combination of Nivolumab and Ipilimumab (Bristol Myers Squibb), Pembrolizumab (Merck), CY-101 (Cytovation), EO2401 combined with Nivolumab (Enterome/Bristol Myers Squibb), OR-449 (Orphagen Pharmaceuticals), and others.
CY-101 is designed to selectively attack and destabilize cancer cell membranes, which leads to the release of tumor-specific neoantigens and enables the immune system to launch a targeted, systemic response against the cancer. In addition, CY-101 blocks the β-catenin signaling pathway, thereby impeding tumor progression and further activating immune defenses. Currently being developed by Cytovation, CY-101 is slated to enter a multi-national Phase II clinical trial for adrenocortical carcinoma in late 2025, with initial data expected in 2026. This study is being conducted in collaboration with Cancer Research UK and the Norwegian Cancer Society, as announced in January 2025.
OR-449 is a first-in-class, orally available inhibitor of the orphan nuclear receptor steroidogenic factor-1 (SF-1, NR5A1), a validated target in ACC—a rare and difficult-to-treat adrenal gland cancer. The U.S. FDA has granted OR-449 Rare Pediatric Disease Designation (RPDD) to support its expedited development for pediatric ACC. Additionally, Orphagen has secured a $10.2 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to fund its IND application and a Phase I trial in adults with ACC. The grant spans three years and requires Orphagen to raise matching funds.
Pembrolizumab, a widely approved PD-1 checkpoint inhibitor, is under evaluation in a Phase II trial for patients with advanced ACC. The trial, sponsored by Memorial Sloan Kettering Cancer Center, is currently in the 'active, not recruiting' phase.
EO2401, a novel microbiome-based therapeutic vaccine developed by Enterome, was aimed at treating solid tumors such as glioblastoma and ACC. However, in November 2024, its Phase I/II SPENCER trial was terminated due to strategic considerations. This development marks a setback in the search for innovative treatments targeting ACC.
The anticipated launch of these emerging adrenocortical carcinoma therapies are poised to transform the adrenocortical carcinoma market landscape in the coming years. As these cutting-edge adrenocortical carcinoma therapies continue to mature and gain regulatory approval, they are expected to reshape the adrenocortical carcinoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about new treatment for adrenocortical carcinoma, visit @ Adrenocortical Carcinoma Management
Recent Developments in the Adrenocortical Carcinoma Market In April 2025, Cytovation announced that it had raised NOK62 million (USD 6 million) largely from existing investors, led by Sandwater. These funds will be used to advance CY-101 into a multi-national Phase II clinical trial in patients with ACC.
announced that it had raised NOK62 million (USD 6 million) largely from existing investors, led by Sandwater. These funds will be used to advance CY-101 into a multi-national Phase II clinical trial in patients with ACC. In November 2024, the status of the Phase I/II SPENCER study was updated to 'terminated,' with the reason cited as a strategic decision. This termination represents a setback in the emerging prospects for developing therapies for ACC.
Adrenocortical Carcinoma Overview
Adrenocortical carcinoma (ACC) is a rare and aggressive cancer that originates in the cortex of the adrenal glands, which are located above the kidneys and are responsible for producing essential hormones such as cortisol, aldosterone, and androgens. ACC can occur at any age but is most commonly diagnosed in children under 5 and adults in their 40s and 50s. The exact causes of ACC are not well understood, but it has been associated with certain genetic syndromes, including Li-Fraumeni syndrome, Beckwith-Wiedemann syndrome, and multiple endocrine neoplasia type 1 (MEN1), which suggests a hereditary component in some cases.
Symptoms of ACC can vary depending on whether the tumor is functioning (hormone-producing) or non-functioning. Functioning tumors may cause signs of hormone excess, such as Cushing's syndrome (weight gain, high blood pressure, muscle weakness, and skin changes), virilization in women (facial hair, deepened voice), or feminization in men. Non-functioning tumors may present later and often manifest as abdominal pain, a palpable mass, or symptoms related to tumor spread, such as weight loss or back pain.
Diagnosis of ACC typically involves a combination of imaging studies and laboratory tests. Imaging techniques such as CT scans or MRI help identify the size, location, and potential spread of the tumor. Hormonal blood and urine tests assess whether the tumor is producing excess hormones. A definitive diagnosis is usually confirmed through histological examination of tissue obtained via biopsy or after surgical removal of the tumor. Early detection is crucial, as ACC often presents at an advanced stage and has a poor prognosis if not treated promptly.
Adrenocortical Carcinoma Epidemiology Segmentation
The adrenocortical carcinoma epidemiology section provides insights into the historical and current adrenocortical carcinoma patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The adrenocortical carcinoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Incident Cases of ACC
Stage-specific Incident Cases of ACC
Gender-specific Incident Cases of ACC
Age-specific Incident Cases of ACC
Download the report to understand which factors are driving adrenocortical carcinoma epidemiology trends @ Adrenocortical Carcinoma Treatment Algorithm Adrenocortical Carcinoma Report Metrics Details Study Period 2020–2034 Adrenocortical Carcinoma Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Adrenocortical Carcinoma Market Size in 2024 USD 30 Million Key Adrenocortical Carcinoma Companies GlaxoSmithKline, Bristol Myers Squibb, Merck, Cytovation, Enterome, Orphagen Pharmaceuticals, and others Key Adrenocortical Carcinoma Therapies CY-101, OR-449, dostarlimab, nivolumab + ipilimumab, and pembrolizumab, EO2401 + Nivolumab, and others
Scope of the Adrenocortical Carcinoma Market Report Adrenocortical Carcinoma Therapeutic Assessment: Adrenocortical Carcinoma current marketed and emerging therapies
Adrenocortical Carcinoma current marketed and emerging therapies Adrenocortical Carcinoma Market Dynamics: Conjoint Analysis of Emerging Adrenocortical Carcinoma Drugs
Conjoint Analysis of Emerging Adrenocortical Carcinoma Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Adrenocortical Carcinoma Market Access and Reimbursement
Discover more about adrenocortical carcinoma drugs in development @ Adrenocortical Carcinoma Clinical Trials
Table of Contents 1. Adrenocortical Carcinoma Market Key Insights 2. Adrenocortical Carcinoma Market Report Introduction 3. Adrenocortical Carcinoma Market Overview at a Glance 4. Adrenocortical Carcinoma Market Executive Summary 5. Disease Background and Overview 6. Adrenocortical Carcinoma Treatment and Management 7. Adrenocortical Carcinoma Epidemiology and Patient Population 8. Patient Journey 9. Adrenocortical Carcinoma Marketed Drugs 10. Adrenocortical Carcinoma Emerging Drugs 11. Seven Major Adrenocortical Carcinoma Market Analysis 12. Adrenocortical Carcinoma Market Outlook 13. Potential of Current and Emerging Therapies 14. KOL Views 15. Unmet Needs 16. SWOT Analysis
Related Reports
Adrenocortical Carcinoma Pipeline
Adrenocortical Carcinoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key adrenocortical carcinoma companies, including Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis, Ipsen, Genentech, among others.
Congenital Adrenal Hyperplasia Market
Congenital Adrenal Hyperplasia Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key congenital adrenal hyperplasia companies, including Crinetics Pharmaceuticals Inc., Diurnal Limited, Adrenas Therapeutics Inc, Neurocrine Biosciences, Spruce Biosciences, among others.
Congenital Adrenal Hyperplasia Pipeline
Congenital Adrenal Hyperplasia Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key congenital adrenal hyperplasia companies, including Neurocrine Biosciences, Spruce Biosciences, Adrenas Therapeutics Inc., Crinetics Pharmaceuticals, Diurnal, among others.
Cushing's Syndrome Market
Cushing's Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Cushing's syndrome companies including Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals, Stero Therapeutics, among others.
DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Pharmaceutical Consulting Services
Healthcare Conference Coverage
Pipeline Assessment
Healthcare Licensing Services
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
21 hours ago
- Hamilton Spectator
The Keg Royalties Income Fund Obtains Unitholder Approval for the Transaction with Fairfax
Not for distribution to U.S. News wire services or dissemination in the U.S. VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) — The Keg Royalties Income Fund (the 'Fund') (TSX: is pleased to announce that, at its special meeting ('Meeting') of the unitholders ('Unitholders') and holders of securities exchangeable into units (the 'Exchangeable Unitholders') of the Fund (the 'Units') held earlier today, Unitholders and Exchangeable Unitholders voted overwhelmingly in favour of the proposed acquisition by 1543965 B.C. Ltd. (the 'Purchaser'), a subsidiary of Fairfax Financial Holdings Limited (the 'Parent') of all of the issued and outstanding units of the Fund not otherwise owned by it and its affiliates (collectively, 'Fairfax') for a price of $18.60 per Unit (the 'Consideration'), payable in cash by way of a statutory plan of arrangement under the Business Corporations Act (British Columbia) in accordance with the arrangement agreement dated June 16, 2025 among the Fund, the Purchaser and the Parent (the 'Arrangement Agreement', and such acquisition and the other transactions contemplated in the Arrangement Agreement, the 'Transaction'). The Arrangement Agreement provides that in addition to the Consideration, Unitholders will be entitled to receive a prorated monthly distribution for the month in which the closing occurs, as well as a special cash distribution based on the Fund's historical practice of paying annual special distributions, with such special cash distribution being set at $0.055 per Unit for the 2025 fiscal year, prorated for the portion of the fiscal year completed as of the closing of the Transaction. The Transaction required the approval of (a) more than two thirds of the votes cast by Unitholders (including for this purpose Exchangeable Unitholders) present in person or represented by proxy at the Meeting, and (b) a simple majority of the votes cast by Unitholders present in person or represented by proxy at the Meeting, excluding the votes of Fairfax and any other Unitholders whose votes were required to be excluded for the purposes of 'minority approval' under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ('MI 61-101'). Of the votes cast at the Meeting with respect to the Transaction, 99.42% were voted in favour of the Transaction. In addition, of the votes cast at the Meeting with respect to the Transaction, excluding those votes required to be excluded pursuant to MI 61-101, 98.79% were voted in favour of the Transaction. A report of voting results for the Meeting will be available on the SEDAR+ profile of the Fund at . The Transaction is structured as a statutory plan of arrangement under the Business Corporations Act (British Columbia) . The Fund and Fairfax intend to seek a final order from the Supreme Court of British Columbia to approve the plan of arrangement on August 7, 2025 (the 'Final Order'). Completion of the Transaction remains subject to the satisfaction or waiver of certain customary closing conditions, including the receipt of the Final Order. Subject to the satisfaction or waiver of all conditions to the Transaction, the Transaction is expected to be completed on or about August 13, 2025. It is expected that the Units will be delisted from the Toronto Stock Exchange in connection with the Transaction. Forward Looking Information This news release contains 'forward-looking information' and 'forward-looking statements' (collectively, 'forward-looking information') within the meaning of applicable securities laws. This information includes, but is not limited to, statements concerning the Fund's objectives, its strategies to achieve those objectives, as well as statements made with respect to the trustees of the Fund's (the 'Trustees') beliefs, plans, estimates, projections and intentions, and similar statements concerning anticipated future events, results, circumstances, performance or expectations that are not historical facts. In some cases, forward-looking information can be identified by the use of forward-looking terminology such as 'expects', 'estimates', 'intends', 'anticipates', 'believes', or variations of such words and phrases or statements that certain actions, events or results 'may', 'could', 'would', 'might', 'will', 'will be taken', 'occur' or 'be achieved'. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent the Trustees' expectations, estimates and projections regarding future events or circumstances. Forward-looking information in this news release, which includes, among other things, statements relating to the closing of the Transaction, the timing thereof and the conditions thereto, including the seeking of the Final Order and the expected delisting of the Units, is necessarily based on a number of opinions and assumptions that the Trustees considered appropriate and reasonable as of the date such statements are made in light of their experience, current conditions and expected future developments. Risks and uncertainties related to the Transaction include, but are not limited to: the possibility that the Transaction will not be completed on the terms and conditions currently contemplated; failure of the Fund and Fairfax to obtain the required court approval for, or satisfy other conditions to effect, the Transaction; and other risk factors contained in filings made by the Fund with the Canadian securities regulators, including the Fund's annual information form dated March 25, 2025 and financial statements and related management discussion and analysis for the financial year ended December 31, 2024 filed with the securities regulatory authorities in certain jurisdictions of Canada and available at . Although the Trustees have attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other risk factors not presently known to them or that they presently believe are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. No forward-looking statement is a guarantee of future results. Accordingly, you should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this news release represents the Fund's expectations as of the date of this news release (or as the date they are otherwise stated to be made) and are subject to change after such date. However, the Fund disclaims any intention or obligation or undertaking to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws in Canada. All of the forward-looking information contained in this news release is expressly qualified by the foregoing cautionary statements. About The Keg Royalties Income Fund The Fund is a limited purpose, open-ended trust established under the laws of the Province of Ontario that, through The Keg Rights Limited Partnership, a subsidiary of the Fund, owns certain trademarks and other related intellectual property used by Keg Restaurants Ltd. ('KRL'). Vancouver-based KRL is the leading operator and franchisor of steakhouse restaurants in Canada and has a substantial presence in select regional markets in the United States. KRL has been named the number one restaurant company to work for in Canada in the latest edition of Forbes 'Canada's Best Employers 2025' survey. About Fairfax Financial Holdings Limited Fairfax Financial Holdings Limited is a holding company which, through its subsidiaries, is primarily engaged in property and casualty insurance and reinsurance and the associated investment management.
Forbes
a day ago
- Forbes
The #1 Quality That Can Help You Overcome Rejection, By A Psychologist
Trying to be accepted and liked by everyone can be exhausting. Research shows that authenticity not only feels better, but also makes rejection hurt way less. getty Have you ever caught yourself shrinking to fit in, maybe quieting your voice, not voicing your opinions or editing out parts of who you are in order to feel accepted? If you relate to this, you're not alone. Many people unconsciously soften themselves to avoid being rejected. When you think of it from an evolutionary perspective, our brains are wired to associate connection with safety. Being left out or, worse, feeling rejected, once meant real danger for our ancestors. So, it makes sense that you might sometimes overcorrect or try hard to shape-shift, blend in and mask your authenticity just to stay connected. In a neuroimaging study published in Science , researchers wanted to explore if the brain processes social pain, like being excluded, similarly to how it processes physical pain. Researchers had the participants play a virtual ball-tossing game. Initially, everyone was included. But eventually, every participant in the study was made to feel left out or excluded in some way by the other players. Researchers observed that in the brain, the anterior cingulate cortex (ACC), a region that also lights up when we experience physical pain (like a burn or a stubbed toe), became more active during the exclusion phase. Moreover, the more it lit up, the more distress the participant reported feeling. This showed that the brain registers rejection like physical pain. This explains why you may try to shrink yourself to fit in. However, the very act of molding yourself constantly can make rejection hurt even more deeply. A 2020 study published in Organizational Behavior and Human Decision Processes explored how feeling authentic, that is, showing up as your true self, could actually reduce the impact of rejection. Across five separate experiments, researchers had the participants engage in different activities that helped them tap into their authentic selves. They reflected on personal values and wrote about a time when they felt most like themselves. Then, participants were placed in situations designed to simulate social exclusion (being left out of a group task or ignored during a conversation). Later, researchers measured how rejected participants felt and how emotionally threatening the situation seemed to them. The findings highlighted how authenticity changed people's emotional and cognitive responses to exclusion. Based on the 2020 study, here are three shifts that happen when you start being true to yourself, that can help you overcome rejection. 1. You See Rejection As Less Threatening You may think of rejection as inherently painful. However, how much rejection hurts depends heavily on how you interpret it. Simply put, when you're being authentic, expressing yourself honestly without trying to perform or please, your perception of rejection becomes different. This is because it doesn't strike the same emotional nerve, and it no longer feels like a judgment of your worth — simply a mismatch. This shift in perception is more powerful than it sounds. In the 2020 study, researchers found that participants who were primed to feel more authentic consistently perceived social exclusion as less threatening. Participants who were acting from their authentic selves experienced lower emotional pain even in situations where they were being left out of a group activity or receiving minimal attention in a simulated interaction. Researchers discovered that reduced threat perception was the key mechanism at play. So, authenticity didn't just make people feel 'better' but also fundamentally altered the way their brains appraised the rejection itself. Their nervous systems treated it as a neutral, even insignificant event instead of interpreting it as a personal danger. Often, when you feel rejected, you may take it personally or take it as proof that you are not good enough, worthy enough or remotely likable. However, when you're authentic, rejection doesn't have that power. It cannot destabilize you since you are not depending on others to validate you. Simply being true to yourself protects your emotional baseline, even if someone walks away. In moments when you feel excluded or rejected, train yourself to take it as a sign of misalignment rather than your inadequacy. A simple question to ask yourself would be, is this rejection threatening who you are or just challenging who you thought you had to be? This can help you shift perspective. The more you build your life around internal truth, the more resilient you become. 2. You Feel Internally Secure And External Feedback Matters Less When you're living in alignment with your authentic self, other people's reactions, whether praise or criticism, can start to lose their grip on your emotional state. You begin to stop performing for approval and expressing what feels true to you. Researchers found that participants who were encouraged to reflect on times they felt authentic showed greater emotional stability in the face of exclusion. This happened because they were less reliant on external cues to 'feel okay'' in the first place. Their sense of self did not come from being chosen, praised or affirmed. So, authenticity cultivates self-concept clarity and a clear and stable understanding of who you are, which acts as a buffer against the emotional highs and lows tied to social feedback. This kind of security is especially important today, in a world where you are constantly exposed to approval metrics such as likes, messages and reactions on social media. Authenticity helps you show up from a place of wholeness, not neediness . This not only protects your peace but also makes your connections more genuine. To start bringing a shift in how secure you feel internally, start noticing where you're still chasing permission, say, moments where you wait for someone else's response to decide how you feel about yourself. Then ask yourself what you would say or do if you didn't need their approval. This is where you start building confidence in your true self. 3. You Experience Lower Threat Perception In General Being authentic doesn't just help you cope with rejection, but also helps you anticipate fewer threats in the first place. Researchers found that authenticity consistently reduced participants' overall perception of social threat , even before any rejection had occurred. They observed that in some cases, just reflecting on an authentic experience was enough to shift participants into a less threatened state. This also meant that they were less likely to misread neutral social cues as hostile, less prone to rumination after exclusion and less reactive in high-pressure group dynamics. So, essentially, authenticity seems to lower baseline psychological threat by signaling to the brain and nervous system that you're safe being who you are. This matters because when you're constantly feeling on edge in social settings, and overthinking how you're being perceived, interpreting silence as judgment or replaying small interactions in your mind, it is your nervous system preparing for rejection. Authenticity interrupts this spiral. You learn that there is nothing to defend. This shift lowers your stress and makes your social life feel more effortless. Over time, it reshapes how safe you feel within yourself and in social situations. Try being mindful of when your mind starts automatically scanning for signs of threat, and if you have anxious thoughts like 'Did they mean that sarcastically?', 'Are they ignoring me?' or 'Should I have said that differently?' Over time, when you start living from a place of authenticity, the need to overanalyze every such social cue reduces. Authenticity Begins Where Perfection Ends Being yourself sounds simple. However, for many, it's easier said than done. This can feel especially hard in a room full of people who expect you to be someone else. In a world where fitting in is often rewarded more than standing out, authenticity can feel risky. However, trying to be someone else will only drain you. Additionally, you don't have to be 'fully healed' or 'perfectly whole' to be authentic. You just have to be honest about who you are. Authenticity isn't about broadcasting your identity with bold declarations. The idea is simply to navigate the world without compromising your truth in exchange for approval. You need to decide to show up as you are, without needing to shrink or stretch yourself to fit. The real power of authenticity is that it does not guarantee social acceptance, but it does teach you how to accept yourself, even when the world doesn't clap for you. Are you shrinking yourself to keep others comfortable? Take this science-backed test to find out who's really in charge of your life: Authenticity In Relationships Scale
Hamilton Spectator
a day ago
- Hamilton Spectator
ThreeD Capital Inc. Completes Private Placement Financing
TORONTO, Aug. 01, 2025 (GLOBE NEWSWIRE) — ThreeD Capital Inc. ('ThreeD' or the 'Company') (CSE:IDK / OTCQX:IDKFF) a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, is pleased to announce that it has closed its previously announced private placement financing (the 'Private Placement') pursuant to which it has issued an aggregate of 11,600,000 units ('Units') of the Company in exchange for total gross proceeds of $696,000, or $0.06 per Unit. Each Unit issued as part of the Private Placement is comprised of one common share and one common share purchase warrant (a 'Warrant'). Each whole Warrant entitles the holder thereof to acquire one common share of the Company at an exercise price of $0.15 per common share for a period of 60 months. No commission or finders' fees were paid as part of the Private Placement. All securities issued and issuable in connection with the Private Placement will be subject to a four-month and a day hold period expiring on December 2, 2025. In connection with the Private Placement, management and directors of the Company (collectively the 'Insiders'), purchased a total of 11,600,000 Units. Insiders' participation in the Private Placement constitutes a 'related party transaction' pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ('MI 61-101'). The Company is relying on the exemption from the valuation and minority shareholder approval requirements under MI 61-101, as the fair market value of the Insiders' participation in the Private Placement does not exceed 25% of the market capitalization of the Company. About ThreeD Capital Inc. ThreeD is a publicly-traded Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors. ThreeD's investment strategy is to invest in multiple private and public companies across a variety of sectors globally. ThreeD seeks to invest in early stage, promising companies where it may be the lead investor and can additionally provide investees with advisory services and access to the Company's ecosystem. For further information: Matthew Davis, CPA Chief Financial Officer and Corporate Secretary info@ Phone: 416-941-8900 The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. Forward-Looking Statements This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as 'forward-looking statements') within the meaning of Canadian securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company's actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.
